WEE1 and Miyoshi myopathy: For the first time, we show that an inhibitor of T‐LAK cell‐originated protein kinase suppressed several MM‐supportive pathways and induced potent MM‐selective killing that synergized with a common component of current treatment regimens, making OTS514 a suitable candidate for targeting in a clinical setting.